---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-004637"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:42:27.706941+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Q1 net loss $173M; $825M Sarepta deal & plozasiran NDA accepted

## Summary
- Net loss of $173M ($1.39 diluted EPS), revenue $2.5M, operating loss $161.4M.
- Sarepta collaboration: $825M upfront ($500M cash + $325M equity at $27.25/share, 35% premium), plus $250M over 5 years, up to $10B milestones.
- Plozasiran NDA for familial chylomicronemia syndrome accepted; PDUFA date Nov 18, 2025.
- Phase 3 PALISADE met primary endpoint; plozasiran reduced triglycerides up to 86% and acute pancreatitis.
- Cash & investments $552.9M; company funded into 2028; obesity programs (ARO-INHBE, ARO-ALK7) entering Phase 1.

## SEC filing metadata
- accession: 0001628280-25-004637
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828025004637/0001628280-25-004637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828025004637/arwr-20250210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-004637
- JSON: https://secwatch.observer/filing/0001628280-25-004637.json
- Plain text: https://secwatch.observer/filing/0001628280-25-004637.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.